Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 28:12:600618.
doi: 10.3389/fphar.2021.600618. eCollection 2021.

PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy

Affiliations
Review

PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy

Ruizhen Huang et al. Front Pharmacol. .

Abstract

Ischemia-reperfusion injury (IRI) is a complex pathophysiological process that is often characterized as a blood circulation disorder caused due to various factors (such as traumatic shock, surgery, organ transplantation, burn, and thrombus). Severe metabolic dysregulation and tissue structure destruction are observed upon restoration of blood flow to the ischemic tissue. Theoretically, IRI can occur in various tissues and organs, including the kidney, liver, myocardium, and brain, among others. The advances made in research regarding restoring tissue perfusion in ischemic areas have been inadequate with regard to decreasing the mortality and infarct size associated with IRI. Hence, the clinical treatment of patients with severe IRI remains a thorny issue. Peroxisome proliferator-activated receptor γ (PPARγ) is a member of a superfamily of nuclear transcription factors activated by agonists and is a promising therapeutic target for ameliorating IRI. Therefore, this review focuses on the role of PPARγ in IRI. The protective effects of PPARγ, such as attenuating oxidative stress, inhibiting inflammatory responses, and antagonizing apoptosis, are described, envisaging certain therapeutic perspectives.

Keywords: Mechanisms; PPARγ; Protective effect; Therapeutic potential; ischemia-reperfusion injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Overview of the possible mechanisms of PPARγ in the organ IRI. The mechanism includes different effects of different PPARγ agonists. NMDA, N-methyl-D-aspartic acid; eNOS, endothelial NO synthase; iNOS, inducible NO synthase; Nrf2, nuclear factor-erythroid 2-related factor 2; RAGE, receptor for advanced glycation end products; SIRT6P, the endogenous retinoid X receptor and sirtuin 6; Fox03a; BBB, blood–brain barrier; MMB, matrix metalloproteinase; TIMPs, tissue inhibitor of metalloproteinase; TXNIP, thioredoxin interacting protein; NLRP3, nod-like receptor family, pyrin domain containing 3; SCP2, sterol carrier protein 2; ACADI, long-chain acyl CoA dehydrogenase; UCP2, mitochondrial uncoupling protein 2.

Similar articles

Cited by

References

    1. Abdelrahman M., Collin M., Thiemermann C. (2004). The peroxisome proliferator-activated RECEPTOR-γ ligand 15-DEOXYD12,14 prostaglandin J2 reduces the organ injury IN hemorrhagic SHOCK. Shock 22, 555–561. 10.1097/01.shk.0000144132.13900.24 - DOI - PubMed
    1. Akahori T., Sho M., Hamada K., Suzaki Y., Kuzumoto Y., Nomi T., et al. (2007). Importance of peroxisome proliferator-activated receptor-γ in hepatic ischemia/reperfusion injury in mice. J. Hepatol. 47, 784–792. 10.1016/j.jhep.2007.07.030 - DOI - PubMed
    1. Ares-Carrasco S., Picatoste B., Camafeita E., Carrasco-Navarro S., Zubiri I., Ortiz A., et al. (2012). Proteome changes in the myocardium of experimental chronic diabetes and hypertension. J. Proteomics 75 (6), 1816–1829. 10.1016/j.jprot.2011.12.023 - DOI - PubMed
    1. Aronoff S., Rosenblatt S., Braithwaite S., Egan J. W., Mathisen A. L., Schneider R. L. (2000). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23, 1605–1611. 10.2337/diacare.23.11.1605 - DOI - PubMed
    1. Azoulay L., Yin H., Filion K. B., Assayag J., Majdan A., Pollak M. N., et al. (2012). The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344, e3645. 10.1136/bmj.e3645 - DOI - PMC - PubMed

LinkOut - more resources